Stock report · Delisted · Nasdaq
Elevation Oncology Inc (ELEV)
0.37USD Delisted Final close · Jul 21, 2025
ELEV no longer trades. Elevation Oncology was delisted from the Nasdaq in July 2025.
All prices on this page are historical. The last trade was on July 21, 2025, at $0.37.
ELEV stock price history
Final trading statistics
- Final close
- $0.37
- Final trading day
- Jul 21, 2025
- Market cap at delisting
- $22.10M
- Shares outstanding
- 59.25M
- Final 52-week range
- $0.22 – $3.09
- Avg. volume (final 3 mo.)
- 1,284,782
- All-time high
- $16.11 · Jul 2021
- All-time low
- $0.23 · Apr 2025
- Return since IPO
- -96.7%
- Beta
- 1.50
- Book value / share
- $0.79
- Price / book
- 0.47
About Elevation Oncology Inc
Elevation Oncology, Inc. was a cancer company developing treatments for solid tumors with high unmet need. Its lead candidate, EO-3021, was an antibody-drug conjugate pairing a fully human anti-Claudin 18.2 antibody with the MMAE payload through a cleavable linker.
EO-3021 was in a Phase 1 trial, alone and combined with dostarlimab (a PD-1 inhibitor) and ramucirumab (a VEGFR2 inhibitor), in advanced or metastatic gastric and gastroesophageal junction tumors. The company licensed EO-3021 from CSPC Megalith Biopharmaceutical Co., Ltd. It was also developing EO-1022, which joins the anti-HER3 antibody seribantumab with MMAE, for HER3-expressing tumors such as breast and non-small cell lung cancer.
Known as 14ner Oncology, Inc. until February 2020, the company was incorporated in 2019 and based in Boston. Its stock was delisted from the Nasdaq in July 2025, with a final trade on July 21, 2025 at $0.37.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA
- Employees
- 34
- IPO date
- June 25, 2021
- Delisted
- July 21, 2025
- SEC CIK
- 1783032
Elevation Oncology financials before the delisting
The last 5 fiscal years Elevation Oncology reported as a public company, fiscal year ending December.
ELEV revenue and net income
ELEV earnings per share
ELEV annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | −$44.5M | −$0.81 |
| FY2023 | $0.00 | −$45.7M | −$1.53 |
| FY2022 | $0.00 | −$95.1M | −$4.09 |
| FY2021 | $0.00 | −$32.0M | −$6.69 |
| FY2020 | $0.00 | −$17.3M | −$1.50 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Elevation Oncology stock FAQ
What happened to Elevation Oncology stock?
Elevation Oncology was delisted from the Nasdaq in July 2025. The final close was $0.37 on July 21, 2025.
Can I still buy ELEV stock?
No. ELEV is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on July 21, 2025.
What was the last price of ELEV?
ELEV last closed at $0.37 on July 21, 2025, which valued the company at about $22.10M.
How did Elevation Oncology do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, Elevation Oncology reported revenue of $0.00 and net income of −$44.5M.
When did Elevation Oncology go public?
Elevation Oncology shares started trading on June 25, 2021.
ELEV no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.